Bowen Acquisition Corp

Status: Live Deal
U=S+R R=S/10
IPO Proceeds, $M $69.00M
IPO Date Jul 12, 2023
CEO Jiangang Luo
Left Lead EarlyBirdCapital
IPO Cash in Trust 101.0%
SPAC Tenor 15 + 3
IPO Sector General

Businesses in Asia

IPO Geography Asia
Target Company Qianzhi BioTech
Deal Announced Jan 18, 2024
Deal Size, $M TBD
Deal Sector Healthcare
Deal Geography Asia
SEC Filings www.sec.gov
Approval Vote Jan 13, 2025
Amendment Vote Jan 7, 2025
BOWN BOWNU BOWNR

Sign up for Free Trial

No credit card required

Sign in for more on Bowen Acquisition Corp:

  • Structure and cap table
  • 6 directors & officers
  • 17 filings and events
  • 2 underwriters
  • 5 legal advisors
Structure

Sign in to view structure, cap table, and calendar of events.

Team
Name Age Title
Na Gai 36 Chairwoman
Jiangang Luo 54 CEO
Jing Lu 58 CFO
Lawrence Leighton 88 Director
Wei Li 44 Director
Jun Zhang 59 Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors
Underwriters
EarlyBirdCapital BR 5,100,000 units
Revere Securities 900,000
6,000,000 units
Up-Front UW fee 2.50 %
BCMA 3.50 %

Sign in to view more advisor data.

Filings
May 19, 2023 Initial S-1
Jun 13, 2023

Sign In to view filing content.

Jul 11, 2023

Sign In to view filing content.

Jul 12, 2023 424B4 IPO Prospectus
Jul 20, 2023

Sign In to view filing content.

Aug 14, 2023

Sign In to view filing content.

Jan 18, 2024

Sign In to view filing content.

Jan 24, 2024

Sign In to view filing content.

Sep 10, 2024

Sign In to view filing content.

Oct 4, 2024

Sign In to view filing content.

Oct 17, 2024

Sign In to view filing content.

Oct 21, 2024

Sign In to view filing content.

Nov 4, 2024 S-4/A Amendment #3 to registration statement containing preliminary proxy for Qianzhi BioTech business combination
Nov 27, 2024

Sign In to view filing content.

Dec 5, 2024

Sign In to view filing content.

Dec 5, 2024

Sign In to view filing content.

Dec 9, 2024

Sign In to view filing content.

Shareholders

Sign in to view shareholders 13F filing data.